Top Health Tools
Top Health Tools

Top Reports
Top Reports
 
Top Articles
Top Articles

Top Reviews
Top Reviews
   

Rotavirus Vaccine Developed By Glaxo
Linked To Convulsions & Pneumonia

GlaxoSmithKline Plc's rotavirus vaccine is associated with increased pneumonia-related deaths and other adverse reactions, U.S. regulatory staff said in recently posted documents.

The review comes ahead of a Food and Drug Administration advisory meeting to consider approval of the oral vaccine to prevent the most common cause of severe diarrhea and dehydration among infants and young children in the world.

FDA staff said its analysis of 11 studies revealed that in the largest trial, there was a statistically significant increase in deaths related to pneumonia compared with placebo, documents posted on the FDA's Web site said.

That study, which enrolled about 63,000 children, also found an increase in convulsions in children given the drug, named Rotarix. Another study found an increased rate of bronchitis, compared with placebo.

In a conclusion section, the FDA documents noted the pneumonia-related deaths and convulsions, but did not appear to make a recommendation to the advisory panel.

That expert panel will weigh the staff review, but makes its own recommendation, which is typically followed by the FDA.

Bernstein Research analyst Tim Anderson said safety issues could mar his current forecasts for the drug of reaching sales of $1.3 billion by 2012.


Reference Source 89
February 20, 2008


Share/Bookmark
...............................................................................................................

This site is owned and operated by PreventDisease.com 1999-2017. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
aaa
Interact
volunteerDonateWrite For Us
Stay Connected With Our Newsletter